Key Points - Investors in Capricor Therapeutics, Inc. (CAPR) are notified of a class action securities lawsuit - Investors who suffered losses are urged to submit their losses for potential recoveries - Allegations of misleading investors regarding the FDA approval process for Deramioce - Capricor Therapeutics experiencing a surge in stock amid updates on Deramiocel...
from Jefferies issued a price target of $1.90 for GEVO on 2026-08-14 20:44:25.The adjusted price target...
Jefferies analyst issues HOLD recommendation for GEVO on August 14, 2026 08:44PM ET. The previous analyst...
from Roth Capital issued a price target of $3.60 for GNSS on 2026-08-14 18:30:10.The adjusted price...
from Industrial Alliance Securities issued a price target of $15.00 for ABEO on 2026-08-14 16:13:37.The adjusted...
from Jefferies issued a price target of $1.90 for GEVO on 2026-08-14 20:44:25.The adjusted price target was set to $1.90.At the time of the announcement, GEVO was trading at $1.69.The...
from Roth Capital issued a price target of $3.60 for GNSS on 2026-08-14 18:30:10.The adjusted price target was set to $3.60.At the time of the announcement, GNSS was trading at...
from Industrial Alliance Securities issued a price target of $15.00 for ABEO on 2026-08-14 16:13:37.The adjusted price target was set to $15.00.At the time of the announcement, ABEO was trading...
Scott Henry from Industrial Alliance Securities issued a price target of $1.90 for QSI on 2026-08-14 13:24:41.The adjusted price target was set to $1.90.At the time of the announcement, QSI...
Joseph Pantginis from H.C. Wainwright issued a price target of $85.00 for RIGL on 2026-08-14 13:12:49.The adjusted price target was set to $85.00.At the time of the announcement, RIGL was...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
